ArticleFrontiers in immunology2012
Subversion and Utilization of Host Innate Defense by Leishmania amazonensis.
Article in Frontiers in immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 57 citations in OpenAlex.
- Mechanisms of Immune Evasion, Dissemination, and Persistence in Leishmania amazonensis Infection.Parasite immunology · 2026Review
- Expression of Network Medicine-Predicted Genes in Human Macrophages Infected withInternational journal of molecular sciences · 2024Article
- Toll-Like Receptor 3 (TLR3) Is Engaged in the Intracellular Survival of the Protozoan ParasiteInfection and immunity · 2022Article
- Comparative transcriptomic analysis of long noncoding RNAs inFrontiers in genetics · 2022Article
- Innate Resistance toFrontiers in microbiology · 2021Article
- Murine Susceptibility toFrontiers in cellular and infection microbiology · 2021Article
- Effect of DODAB Nano-Sized Cationic Bilayer Fragments againstMolecules (Basel, Switzerland) · 2020Article
- Ascorbate-Dependent Peroxidase (APX) from Leishmania amazonensis Is a Reactive Oxygen Species-Induced Essential Enzyme That Regulates Virulence.Infection and immunity · 2019Article
- ATP6V0d2 controls Leishmania parasitophorous vacuole biogenesis via cholesterol homeostasis.PLoS pathogens · 2019Article
- Characterization of Sv129 Mice as a Susceptible Model toFrontiers in medicine · 2019Article
- Efficacy of FourMedicines (Basel, Switzerland) · 2018Article
- Extracellular Vesicles Released byFrontiers in microbiology · 2018Article
- Emerging Role for the PERK/eIF2α/ATF4 in Human Cutaneous Leishmaniasis.Scientific reports · 2017Article
- IL-32γ promotes the healing of murine cutaneous lesions caused by Leishmania braziliensis infection in contrast to Leishmania amazonensis.Parasites & vectors · 2017Article
- Systems Approach Reveals Nuclear Factor Erythroid 2-Related Factor 2/Protein Kinase R Crosstalk in Human Cutaneous Leishmaniasis.Frontiers in immunology · 2017Article
- Effects of Bone Marrow Mesenchymal Stromal Cell Therapy in Experimental Cutaneous Leishmaniasis in BALB/c Mice Induced byFrontiers in immunology · 2017Article
- Differences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discovery.Parasites & vectors · 2016Review
- Leishmania amazonensis Engages CD36 to Drive Parasitophorous Vacuole Maturation.PLoS pathogens · 2016Article
- Cutaneous Leishmaniasis Vaccination: A Matter of Quality.Frontiers in immunology · 2016Review
- Permissive and protective roles for neutrophils in leishmaniasis.Clinical and experimental immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Infection with Leishmania amazonensis and other members of the Leishmania mexicana complex can lead to diverse clinical manifestations, some of which are relatively difficult to control, even with standard chemotherapy. Diffuse cutaneous leishmaniasis (CL) is a rare but severe form, and its clinical hallmark is excessive parasitic growth in infected cells accompanied by profound impairments in host immune responses to the parasites. Since these parasites also cause non-healing CL in most inbred strains of mice, these animals are valuable models for dissecting the mechanisms of persistent infection and disease pathogenesis. In comparison to other Leishmania species, L. amazonensis infections are most remarkable for their ability to repress the activation and effector functions of macrophages, dendritic cells, and CD4(+) T cells, implying discrete mechanisms at work. In addition to this multilateral suppression of host innate and adaptive immunity, the activation of types I and II interferon-mediated responses and autophagic/lipid metabolic pathways actually promotes rather than restrains L. amazonensis infection. These seemingly contradictory findings reflect the remarkable adaptation of the parasites to the ancient defense machinery of the host, as well as the complex parasite-host interactions at different stages of infection, which collectively contribute to non-healing leishmaniasis in the New World. This review article highlights new evidence that reveals the strategies utilized by L. amazonensis parasites to subvert or modulate host innate defense machinery in neutrophils and macrophages, as well as the regulatory roles of host innate responses in promoting parasite survival and replication within the huge parasitophorous vacuoles. A better understanding of unique features in host responses to these parasites at early and late stages of infection is important for the rational design of control strategies for non-healing leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.